603168 莎普爱思
已收盘 05-28 15:00:00
资讯
新帖
简况
莎普爱思（603168）披露实际控制人股份解质押公告，5月26日股价下跌2.63%
证券之星 · 05-26 22:48
莎普爱思（603168）披露实际控制人股份解质押公告，5月26日股价下跌2.63%
莎普爱思(603168.SH)：获得枸橼酸西地那非口崩片《药品注册证书》
智通财经 · 05-25
莎普爱思(603168.SH)：获得枸橼酸西地那非口崩片《药品注册证书》
股市必读：莎普爱思（603168）5月18日披露最新机构调研信息
证券之星 · 05-19
股市必读：莎普爱思（603168）5月18日披露最新机构调研信息
每周股票复盘：莎普爱思（603168）终止收购勤礼实业股权
证券之星 · 05-10
每周股票复盘：莎普爱思（603168）终止收购勤礼实业股权
时安生物与GSK就寡核苷酸新药达成超10亿美元授权合作；莎普爱思终止购买上海勤礼实业100%股权｜医药早参
每日经济新闻 · 05-07
时安生物与GSK就寡核苷酸新药达成超10亿美元授权合作；莎普爱思终止购买上海勤礼实业100%股权｜医药早参
莎普爱思(603168.SH)拟终止购买上海勤礼实业有限公司100%股权事项
智通财经 · 05-06
莎普爱思(603168.SH)拟终止购买上海勤礼实业有限公司100%股权事项
股市必读：莎普爱思(603168)股东户数2.66万户，较上期增加4.99%
证券之星 · 05-06
股市必读：莎普爱思(603168)股东户数2.66万户，较上期增加4.99%
每周股票复盘：莎普爱思（603168）Q1净利降394.89%
证券之星 · 05-02
每周股票复盘：莎普爱思（603168）Q1净利降394.89%
莎普爱思（603168）披露2026年第一季度报告，4月29日股价上涨1.81%
证券之星 · 04-29
莎普爱思（603168）披露2026年第一季度报告，4月29日股价上涨1.81%
图解莎普爱思一季报：第一季度单季净利润同比下降394.89%
证券之星 · 04-29
图解莎普爱思一季报：第一季度单季净利润同比下降394.89%
每周股票复盘：莎普爱思（603168）2025年净亏损2.39亿元
证券之星 · 04-19
每周股票复盘：莎普爱思（603168）2025年净亏损2.39亿元
股市必读：莎普爱思年报 - 第四季度单季净利润同比下降187.37%
证券之星 · 04-16
股市必读：莎普爱思年报 - 第四季度单季净利润同比下降187.37%
莎普爱思(603168.SH)发布2025年度业绩，归母净亏损2.39亿元
智通财经 · 04-14
莎普爱思(603168.SH)发布2025年度业绩，归母净亏损2.39亿元
每周股票复盘：莎普爱思（603168）签署7100万元专利转让合同
证券之星 · 04-05
每周股票复盘：莎普爱思（603168）签署7100万元专利转让合同
持续打击医保药品领域违法违规问题；中国首个原创核药获批
21世纪经济报道 · 04-03
持续打击医保药品领域违法违规问题；中国首个原创核药获批
莎普爱思(603168.SH)与温医大眼视光医院等签署技术转让合同
智通财经 · 04-02
莎普爱思(603168.SH)与温医大眼视光医院等签署技术转让合同
再次延期回复！莎普爱思5.28亿元收购上海勤礼引监管火速问询：高估值、高对赌、低现金、缺信披四大疑点待解
蓝鲸财经 · 03-31
再次延期回复！莎普爱思5.28亿元收购上海勤礼引监管火速问询：高估值、高对赌、低现金、缺信披四大疑点待解
每周股票复盘：莎普爱思（603168）收投服中心建议函质疑收购
证券之星 · 03-29
每周股票复盘：莎普爱思（603168）收投服中心建议函质疑收购
股市必读：新发布《浙江莎普爱思药业股份有限公司关于延期回复上海证券交易所问询函的公告》
证券之星 · 03-26
股市必读：新发布《浙江莎普爱思药业股份有限公司关于延期回复上海证券交易所问询函的公告》
莎普爱思拟溢价24倍收购关联方旗下医院引质疑，中证投服中心追问几大疑点
每日经济新闻 · 03-25
莎普爱思拟溢价24倍收购关联方旗下医院引质疑，中证投服中心追问几大疑点
加载更多
公司概况
公司名称：
浙江莎普爱思药业股份有限公司
所属行业：
医药制造业
上市日期：
2014-07-02
主营业务：
浙江莎普爱思药业股份有限公司的主营业务是药品研发、生产、销售及医疗服务。公司的主要产品是苄达赖氨酸滴眼液、头孢克肟、玻璃酸钠滴眼液、左氧氟沙星滴眼液。公司荣膺2025年度长兴金奖·中国药店甄选品牌、莎普爱思玻璃酸钠滴眼液获西湖奖·最受药店欢迎的明星单品。
发行价格：
21.85
{"stockData":{"symbol":"603168","market":"SH","secType":"STK","nameCN":"莎普爱思","latestPrice":5.86,"timestamp":1779951601000,"preClose":5.85,"halted":0,"volume":7343116,"delay":0,"changeRate":0.0017,"floatShares":373000000,"shares":374000000,"eps":-0.7316,"marketStatus":"已收盘","change":0.01,"latestTime":"05-28 15:00:00","open":5.84,"high":5.91,"low":5.66,"amount":42630000,"amplitude":0.0427,"askPrice":5.86,"askSize":169,"bidPrice":5.85,"bidSize":416,"shortable":0,"etf":0,"ttmEps":-0.7316,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780018200000},"marketStatusCode":5,"adr":0,"adjPreClose":5.85,"symbolType":"stock","openAndCloseTimeList":[[1779931800000,1779939000000],[1779944400000,1779951600000]],"highLimit":6.44,"lowLimit":5.27,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":374126505,"isCdr":false,"pbRate":1.65,"roa":"--","roe":"--","epsLYR":-0.64,"committee":0.259145,"marketValue":2192000000,"turnoverRate":0.0197,"status":0,"floatMarketCap":2183000000},"requestUrl":"/m/hq/s/603168/","defaultTab":"news","newsList":[{"id":"2638543258","title":"莎普爱思（603168）披露实际控制人股份解质押公告，5月26日股价下跌2.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638543258","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638543258?lang=zh_cn&edition=full","pubTime":"2026-05-26 22:48","pubTimestamp":1779806900,"startTime":"0","endTime":"0","summary":"截至2026年5月26日收盘，莎普爱思报收于5.92元，较前一交易日下跌2.63%，最新总市值为22.15亿元。近日，莎普爱思发布《关于实际控制人股份解质押的公告》。公告显示，公司实际控制人林弘远及其一致行动人合计持有公司股份121,965,305股，占公司总股本的32.60%。林弘远于2026年5月22日解除质押11,013,700股，占其持股的38.04%，占公司总股本的2.94%。本次解押后，林弘远及其一致行动人累计质押股份42,612,083股，占其持股总数的34.94%，占公司总股本的11.39%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600041506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603168"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638536462","title":"莎普爱思(603168.SH)：获得枸橼酸西地那非口崩片《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2638536462","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638536462?lang=zh_cn&edition=full","pubTime":"2026-05-25 16:40","pubTimestamp":1779698405,"startTime":"0","endTime":"0","summary":"智通财经APP讯，莎普爱思(603168.SH)发布公告，近日，公司收到国家药品监督管理局核发的枸橼酸西地那非口崩片的《药品注册证书》。据悉，本次获批的枸橼酸西地那非口崩片适用于治疗勃起功能障碍。截至本公告披露日，公司针对该药品的累计研发投入约为991.5万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"莎普爱思(603168.SH)：获得枸橼酸西地那非口崩片《药品注册证书》","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603168","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636100399","title":"股市必读：莎普爱思（603168）5月18日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2636100399","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636100399?lang=zh_cn&edition=full","pubTime":"2026-05-19 01:59","pubTimestamp":1779127149,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，莎普爱思报收于6.38元，下跌0.31%，换手率2.03%，成交量7.57万手，成交额4783.43万元。机构调研要点苄达赖氨酸滴眼液一致性评价方面，2026年度公司持续推进相关工作，已完成上市后临床研究并上报国家药监局，后续进展将依规履行信息披露义务。公司目前暂无购股份计划，如有将严格按照监管要求履行信息披露义务。后续分红恢复条件详见公司2026年4月15日披露的《莎普爱思未来三年股东分红回报规划》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900002211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603168","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634412183","title":"每周股票复盘：莎普爱思（603168）终止收购勤礼实业股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2634412183","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634412183?lang=zh_cn&edition=full","pubTime":"2026-05-10 03:29","pubTimestamp":1778354949,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，莎普爱思报收于6.71元，较上周的6.74元下跌0.45%。本周，莎普爱思5月6日盘中最高价报6.8元。本周关注点公司公告汇总：莎普爱思决定终止拟购买上海勤礼实业有限公司100%股权暨关联交易事项。公司公告汇总莎普爱思第六届董事会第十五次会议于2026年5月6日以通讯方式召开，应出席董事9人，实际出席9人，会议决议合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000001395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603168","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633512166","title":"时安生物与GSK就寡核苷酸新药达成超10亿美元授权合作；莎普爱思终止购买上海勤礼实业100%股权｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2633512166","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633512166?lang=zh_cn&edition=full","pubTime":"2026-05-07 07:00","pubTimestamp":1778108408,"startTime":"0","endTime":"0","summary":"丨2026年5月7日星期四丨NO.1时安生物与GSK就寡核苷酸新药达成超10亿美元授权合作时安生物宣布，与葛兰素史克（GSK）就SA030达成一项中国市场以外的全球独家许可协议。葛兰素史克将支付首付款，以及未来基于成功达成的开发、注册与商业化里程碑付款，总额最高达10.05亿美元；同时将按中国以外的全球产品净销售额支付分级特许权使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605073729101163.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605073729101163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","BK1574","GSK.UK","BK4588","GSKH","BK1161","BK1515","159938","LU1829250122.USD","BK4007","GSK","BK4532","603168","BK0239","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633108188","title":"莎普爱思(603168.SH)拟终止购买上海勤礼实业有限公司100%股权事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2633108188","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633108188?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:17","pubTimestamp":1778059032,"startTime":"0","endTime":"0","summary":"智通财经APP讯，莎普爱思(603168.SH)发布公告，公司决定终止购买上海勤礼实业有限公司100%股权暨关联交易的事项。本次终止购买股权暨关联交易事项不会影响公司的正常经营，不会对公司的经营发展和财务状况产生不良影响，不会损害公司及全体股东的利益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","603168"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633692798","title":"股市必读：莎普爱思(603168)股东户数2.66万户，较上期增加4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633692798","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633692798?lang=zh_cn&edition=full","pubTime":"2026-05-06 05:20","pubTimestamp":1778016023,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，莎普爱思报收于6.74元，上涨0.0%，换手率2.27%，成交量8.46万手，成交额5673.7万元。来自公司公告汇总：莎普爱思第六届董事会第十四次会议审议通过《关于2026年第一季度报告的议案》，决议合法有效。股本股东变化股东户数变动截至2026年3月31日公司股东户数为2.66万户，较12月31日增加1263.0户，增幅为4.99%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600003744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603168","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632013628","title":"每周股票复盘：莎普爱思（603168）Q1净利降394.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632013628","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632013628?lang=zh_cn&edition=full","pubTime":"2026-05-02 05:47","pubTimestamp":1777672031,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，莎普爱思报收于6.74元，较上周的6.5元上涨3.69%。本周，莎普爱思4月29日盘中最高价报6.8元。股本股东变化截至2026年3月31日，莎普爱思股东户数为2.66万户，较2025年12月31日增加1263.0户，增幅4.99%。公司公告汇总浙江莎普爱思药业股份有限公司2026年第一季度报告显示，报告期内营业收入为98,522,734.42元，同比下降3.15%；利润总额为-25,814,816.70元，上年同期为9,047,476.95元；归属于上市公司股东的净利润为-26,104,017.00元，同比下降394.89%；基本每股收益为-0.07元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603168","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631254829","title":"莎普爱思（603168）披露2026年第一季度报告，4月29日股价上涨1.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631254829","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631254829?lang=zh_cn&edition=full","pubTime":"2026-04-29 22:16","pubTimestamp":1777472197,"startTime":"0","endTime":"0","summary":"截至2026年4月29日收盘，莎普爱思报收于6.74元，较前一交易日上涨1.81%，最新总市值为25.22亿元。该股当日开盘6.62元，最高6.8元，最低6.55元，成交额达5286.15万元，换手率为2.11%。近日，浙江莎普爱思药业股份有限公司披露《2026年第一季度报告》。总资产为1,771,047,991.09元，较上年度末的1,872,251,085.55元下降5.41%；归属于上市公司股东的所有者权益为1,325,076,187.20元，较上年度末减少1.93%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900068742.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603168"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631516789","title":"图解莎普爱思一季报：第一季度单季净利润同比下降394.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631516789","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631516789?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:58","pubTimestamp":1777463908,"startTime":"0","endTime":"0","summary":"证券之星消息，莎普爱思2026年一季报显示，一季度公司主营收入9852.27万元，同比下降3.15%；归母净利润-2610.4万元，同比下降394.89%；扣非净利润18.56万元，同比上升116.21%；负债率25.18%，投资收益-2089.77万元，财务费用196.9万元，毛利率50.79%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900061050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603168"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628597837","title":"每周股票复盘：莎普爱思（603168）2025年净亏损2.39亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628597837","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628597837?lang=zh_cn&edition=full","pubTime":"2026-04-19 03:03","pubTimestamp":1776538988,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，莎普爱思报收于6.51元，较上周的6.87元下跌5.24%。本周，莎普爱思4月13日盘中最高价报6.95元。莎普爱思当前最新总市值24.36亿元，在化学制药板块市值排名142/150，在两市A股市值排名4944/5198。本周关注点来自业绩披露要点：莎普爱思2025年归母净利润为-2.39亿元，同比下降93.39%。股本股东变化股东户数变动截至2026年3月31日，莎普爱思股东户数为2.66万户，较2025年12月31日增加1263户，增幅4.99%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900001019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603168","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627317222","title":"股市必读：莎普爱思年报 - 第四季度单季净利润同比下降187.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627317222","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627317222?lang=zh_cn&edition=full","pubTime":"2026-04-16 01:40","pubTimestamp":1776274820,"startTime":"0","endTime":"0","summary":"来自业绩披露要点：莎普爱思2025年归母净利润亏损2.39亿元，同比下降93.39%。业绩披露要点财务报告莎普爱思2025年年报显示，当年度公司主营收入4.63亿元，同比下降4.38%；归母净利润-2.39亿元，同比下降93.39%；扣非净利润-2.81亿元，同比下降163.59%；其中2025年第四季度，公司单季度主营收入1.12亿元，同比下降9.96%；单季度归母净利润-2.66亿元，同比下降187.37%；单季度扣非净利润-2.86亿元，同比下降405.45%；负债率27.83%，投资收益2861.58万元，财务费用898.07万元，毛利率45.96%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600002232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603168"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627443591","title":"莎普爱思(603168.SH)发布2025年度业绩，归母净亏损2.39亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627443591","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627443591?lang=zh_cn&edition=full","pubTime":"2026-04-14 19:32","pubTimestamp":1776166341,"startTime":"0","endTime":"0","summary":"智通财经APP讯，莎普爱思(603168.SH)发布2025年年度报告，报告期内，公司实现营业收入4.63亿元，同比下降4.38%。归属于上市公司股东的净亏损2.39亿元，归属于上市公司股东的扣除非经常性损益的净亏损2.81亿元，基本每股亏损0.64元。本期业绩亏损主要原因包括：(1)诊疗服务板块收入及毛利下滑;(2)因市场环境变化，诊疗服务板块业务增长未达预期，本报告期泰州医院、青岛视康医院计提大额商誉减值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428450.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"莎普爱思(603168.SH)发布2025年度业绩，归母净亏损2.39亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603168","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625619285","title":"每周股票复盘：莎普爱思（603168）签署7100万元专利转让合同","url":"https://stock-news.laohu8.com/highlight/detail?id=2625619285","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625619285?lang=zh_cn&edition=full","pubTime":"2026-04-05 03:23","pubTimestamp":1775330590,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，莎普爱思报收于6.81元，较上周的6.93元下跌1.73%。本周，莎普爱思3月31日盘中最高价报7.22元。本周关注点公司公告汇总：莎普爱思签署7100万元专利转让合同及未来销售提成。公司公告汇总浙江莎普爱思药业股份有限公司于2026年3月17日收到上海证券交易所下发的《关于公司向关联方购买资产相关事项的问询函》，要求在5个交易日内回复。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603168","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624313635","title":"持续打击医保药品领域违法违规问题；中国首个原创核药获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2624313635","media":"21世纪经济报道","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624313635?lang=zh_cn&edition=full","pubTime":"2026-04-03 08:02","pubTimestamp":1775174556,"startTime":"0","endTime":"0","summary":"政策动向国家医保局持续开展打击医保药品领域违法违规问题专项行动近日国家医保局办公室印发《关于深入开展打击医保药品领域违法违规问题专项行动的通知》，对持续打击倒卖医保“回流药”等违法违规问题进行专门部署。《通知》要求，自2026年4月起，以药品追溯码疑点线索核查为抓手，在全国范围内继续深入开展打击医保药品领域违法违规问题专项行动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604033694126468.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604033694126468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK0239","688520","ADC","BK1161","06978","AGIX","BK4080","CHAT","603168","BK4231","BK1588","LU2488822045.USD","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624579828","title":"莎普爱思(603168.SH)与温医大眼视光医院等签署技术转让合同","url":"https://stock-news.laohu8.com/highlight/detail?id=2624579828","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624579828?lang=zh_cn&edition=full","pubTime":"2026-04-02 15:54","pubTimestamp":1775116460,"startTime":"0","endTime":"0","summary":"智通财经APP讯，莎普爱思(603168.SH)公告，公司与温州医科大学附属眼视光医院(简称“温医大眼视光医院”)、周翔天教授签署了《技术转让(专利权)合同》，温医大眼视光医院将其名(包括海外申请对应的中译名)为“一种采用SPAS-26021治疗近视的方法”的10项合作产品核心专利、合作产品专有技术及相关权益全部转让给公司，转让价格为7100万元以及合作产品上市后的销售提成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603168","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623397307","title":"再次延期回复！莎普爱思5.28亿元收购上海勤礼引监管火速问询：高估值、高对赌、低现金、缺信披四大疑点待解","url":"https://stock-news.laohu8.com/highlight/detail?id=2623397307","media":"蓝鲸财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623397307?lang=zh_cn&edition=full","pubTime":"2026-03-31 17:33","pubTimestamp":1774949614,"startTime":"0","endTime":"0","summary":"3月17日，莎普爱思披露拟以5.28亿元现金收购控股股东养和实业及一致行动人谊和医疗持有的上海勤礼100%股权，进而间接取得上海天伦医院控制权。公告次日，上交所即下发问询函，直指本次交易估值畸高、业绩承诺缺乏支撑、资金来源存疑等核心问题。公司两次申请延期回复，截至4月1日仍未完成正式答复。截至2025年三季度末，莎普爱思货币资金余额为1.01亿元，交易性金融资产为1.22亿元，合计2.23亿元，远低于首两期合计约3.70亿元的付款义务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1774949359502091663","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["603168","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623533380","title":"每周股票复盘：莎普爱思（603168）收投服中心建议函质疑收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2623533380","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623533380?lang=zh_cn&edition=full","pubTime":"2026-03-29 04:08","pubTimestamp":1774728491,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，莎普爱思报收于6.93元，较上周的6.88元上涨0.73%。本周，莎普爱思3月27日盘中最高价报6.94元。浙江莎普爱思药业股份有限公司于2026年3月24日收到中证中小投资者服务中心《股东建议函》，针对公司拟以5.28亿元现金收购控股股东及其一致行动人持有的上海勤礼实业有限公司100%股权事项提出质疑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900001004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603168","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622093310","title":"股市必读：新发布《浙江莎普爱思药业股份有限公司关于延期回复上海证券交易所问询函的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2622093310","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622093310?lang=zh_cn&edition=full","pubTime":"2026-03-26 02:27","pubTimestamp":1774463231,"startTime":"0","endTime":"0","summary":"公司公告汇总浙江莎普爱思药业股份有限公司关于延期回复上海证券交易所问询函的公告浙江莎普爱思药业股份有限公司于2026年3月17日收到上海证券交易所下发的《关于向关联方购买资产相关事项的问询函》，要求在5个交易日内书面回复。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600002654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603168","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622878045","title":"莎普爱思拟溢价24倍收购关联方旗下医院引质疑，中证投服中心追问几大疑点","url":"https://stock-news.laohu8.com/highlight/detail?id=2622878045","media":"每日经济新闻","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622878045?lang=zh_cn&edition=full","pubTime":"2026-03-25 10:21","pubTimestamp":1774405260,"startTime":"0","endTime":"0","summary":" 近期，一笔溢价高达24倍的关联收购，将莎普爱思推上了风口浪尖。 3月24日，莎普爱思公告称，公司曾于今年3月17日收到上海证券交易所关于公司向关联方购买资产相关事项的问询函。 同日，莎普爱思还披露其收到中证中小投资者服务中心发来的《股东建议函》。中证投服中心称，对标的公司近两年经营业绩大幅增长的原因、本次交易估值的合理性尚存疑问，现依法行使股东建议权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-03-25/doc-inhseiya6903716.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-03-25/doc-inhseiya6903716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","603168"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779978687256,"stockEarnings":[{"period":"1week","weight":-0.0802},{"period":"1month","weight":-0.1176},{"period":"3month","weight":-0.2169},{"period":"6month","weight":-0.2697},{"period":"1year","weight":-0.2062},{"period":"ytd","weight":-0.2052}],"compareEarnings":[{"period":"1week","weight":-0.0164},{"period":"1month","weight":0.0018},{"period":"3month","weight":-0.0128},{"period":"6month","weight":0.0528},{"period":"1year","weight":0.2254},{"period":"ytd","weight":0.0315}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江莎普爱思药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"26587人(较上一季度增加4.99%)","perCapita":"14011股","listingDate":"2014-07-02","address":"浙江省嘉兴市平湖市经济开发区新明路1588号","registeredCapital":"37412万元","survey":" 浙江莎普爱思药业股份有限公司的主营业务是药品研发、生产、销售及医疗服务。公司的主要产品是苄达赖氨酸滴眼液、头孢克肟、玻璃酸钠滴眼液、左氧氟沙星滴眼液。公司荣膺2025年度长兴金奖·中国药店甄选品牌、莎普爱思玻璃酸钠滴眼液获西湖奖·最受药店欢迎的明星单品。","listedPrice":21.85},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"莎普爱思(603168)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供莎普爱思(603168)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"莎普爱思,603168,莎普爱思股票,莎普爱思股票老虎,莎普爱思股票老虎国际,莎普爱思行情,莎普爱思股票行情,莎普爱思股价,莎普爱思股市,莎普爱思股票价格,莎普爱思股票交易,莎普爱思股票购买,莎普爱思股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"莎普爱思(603168)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供莎普爱思(603168)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}